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Purpose: Transdermal electroporation has become one of the most promising noninvasive 
methods for drug administration, with greatly increased transport of macromolecules through 
the skin. The cecal-contracting effects of repeated transdermal electroporation delivery and 
intravenous administration of neostigmine were compared in anesthetized rats.
Methods: The cecal contractions were detected with implantable strain gauge sensors, and the 
plasma levels of neostigmine were followed by high-performance liquid chromatography.
Results: Both intravenously and EP-administered neostigmine (0.2–66.7 μg/kg) increased the 
cecal contractions in a dose-dependent manner. For both the low doses and the highest dose, 
the neostigmine plasma concentrations were the same after the two modes of administration, 
while an insignificantly higher level was observed at a dose of 20 μg/kg after intravenous 
administration as compared with the electroporation route. The contractile responses did not 
differ significantly after the two administration routes.
Conclusion: The results suggest that electroporation-delivered neostigmine elicits action 
equivalent to that observed after intravenous administration as concerning both time and intensity. 
Electroporation permits the delivery of even lower doses of water-soluble compounds through 
the skin, which is very promising for clinical practice.
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Introduction
Since the emergence of electroporation (EP) in the early 1980s, it has received appre-
ciable attention in both chemotherapy and gene therapy. With this method, reversible 
perturbation of the lipid membrane is induced with electrical pulses. The EP could be 
induced by a large variety of pulses: high-voltage pulses which are typically short, low-
voltage pulses which are typically longer, or a combination of high- and low-voltage 
pulses.1,2 Electrochemotherapy involves EP of intratumorally or intravenously (iv) 
administered cytotoxic drugs, and serves as an excellent alternative for the therapy of 
cutaneous and subcutaneous metastases.3–6 Furthermore, the delivery of gene-based 
drugs and DNA vaccines by EP enhances the transgene expression in the muscle by two 
to three orders of magnitude.7 EP also seems to be suitable for extended transdermal 
drug delivery, modifying the multilamellar lipid bilayers of the stratum corneum.8–10
The morphology and the special composition of the stratum corneum make it an 
impermeable barrier for water-soluble compounds. The stratum corneum consists of 
keratin-rich enucleate nonviable cells (corneocytes) embedded in an intercellular matrix 
of multilamellar lipid bilayers. Only a few drugs are able to pass through the skin with-
out the aid of a penetration enhancer.11 Transdermal delivery of drugs by EP was first 
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suggested by Prausnitz et al12 to enhance their bioavailability. 
Drugs administered transdermally have higher bioavailability 
than when they are used orally, thanks to their avoidance of 
the hepatic first-pass metabolism and gastric acid. On the 
other hand, transdermal administration protects the gastro-
intestinal system from direct irritation by the drugs.
Transdermal EP is currently one of the most promising 
modes of physical enhancement for the noninvasive transder-
mal delivery of lipophilic, hydrophilic, and charged or neutral 
molecules or macromolecules. The transdermal transport of 
drugs with molecular weight up to 40 kDa across the skin can 
thereby be increased by several orders of magnitude.8,13 Appro-
priate transdermal transport necessitates the adjustment of the 
voltage, pulse duration, and number of series of impulses.14
In the present study, the model drug chosen for EP was 
neostigmine methylsulfate, a reversible acetylcholinesterase 
inhibitor and an inducer of gastrointestinal motility. Neostig-
mine has only poor bioavailability after oral administration; 
its effective parenteral dose for humans is 0.5 to 2.0 mg, 
while the equivalent oral dose should be 30 mg or more, 
but large oral doses may cause toxic effects.15 Neostigmine 
methylsulfate (molecular weight: 334.39 g/mol, log P: −2.2) 
is not able to permeate through the skin because of its low 
penetration through the stratum corneum.
We set out to investigate the gastrointestinal effects 
of repeated transdermal administration of neostigmine by 
EP and compare the systemic effects of EP-delivered and 
iv-administered neostigmine. The plasma neostigmine levels 
were followed in both cases.
Materials and methods
housing and handling of the animals
All animals were treated in full accordance with the European 
Communities Council Directives (86/609/ECC) and the 
Hungarian Act for the Protection of Animals in Research 
(XXVIII.tv.32.§). All experiments involving animal subjects 
were carried out under sterile conditions with the approval 
of the Hungarian Ethical Committee for Animal Research 
(registration number: IV/198/2013).
All animal-handling procedures were performed accord-
ing to the Guide for the Care and Use of Laboratory Ani-
mals of the National Institutes of Health and followed the 
guidelines of the Animal Welfare Act. Sprague-Dawley 
rats (Charles-River Laboratories, Budapest, Hungary) were 
housed at 22°C±3°C in a relative humidity of 30%–70% 
under a 12-hour light/dark cycle. Pellet food (Charles-River 
Laboratories) and tap water were provided ad libitum.
experimental design and contractility 
measurement
The experimental design is represented in Figure 1. Male 
Sprague-Dawley rats (6–7 weeks old, body weight: 190–220 g) 
participated either in repeated iv (n=10) or transdermal EP 
treatment (n=8) with neostigmine methylsulfate (Teva Phar-
maceutical Industries Ltd., Gödöllő, Hungary). Throughout 
the experiment, the animals were kept under deep anesthesia 
with a combination of intraperitoneal ketamine and xylazine 
(36 and 4 mg/kg, respectively). The jugular vein was can-
nulated for drug administration and the carotid artery for 
blood collection. The abdominal cavity was opened and an 
implantable force/displacement transducer or strain gauge 
(EGG-01 SG; Experimetria, Budapest, Hungary) was sutured 
onto the surface of the cecum. The animals were then placed 
onto a 37°C heated operating table (EXP-D-TC/MA-02; 
Experimetria) in order to maintain the body temperature. The 
strain gauge converted the cecal mechanical contractions to 
electrical signals. The amplified signals were recorded and 
analyzed with an online computer by the S.P.E.L. Advanced 
ISOSYS Data Acquisition System (Experimetria). The basal 
contractions were detected for at least 10 minutes before the 
first dose of neostigmine. The area under the curve of these 
10 minutes was used as the control, and the stimulation was 
Figure 1 The experimental design for the investigation of the effect of neostigmine by eP administration.
Notes: (A) implantation of strain gauge on the surface of the cecum. (B) Placement of eP headpiece on the abdominal skin after closing the abdomen.
Abbreviation: eP, electroporation.
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calculated as a percentage of this initial period. Following the 
addition of each concentration of neostigmine, the area under 
the curve of a 10-minute period was evaluated. The effects 
were expressed as percentages of the basal activity. Three-
parameter, symmetrical sigmoidal concentration–response 
curves were fitted. The ED
50
 values, that is, the doses that pro-
voke a response half way between the basal and the maximal 
response, were calculated and the unpaired t-test was applied 
for statistical analysis with the Prism 5.0 computer program 
(GraphPad Software, Inc., La Jolla, CA, USA).
eP protocols
Before EP, the rats were shaved on the abdominal surface 
and the remaining hair was removed with Veet depilatory 
cream (Reckit Benckiser, Bristol, UK).
Neostigmine was administered in cumulative doses of 0.2, 
0.67, 2.0, 6.7, 20.0, and 66.7 μg/kg. For EP, neostigmine meth-
ylsulfate was dissolved in a 2.5% hydroxyethylcellulose-con-
taining hydrogel (Natrosol™ HEC, Ashland Inc., Covington, 
KY, USA). The final volume of the neostigmine-containing 
hydrogel was 25 μL and the pH of the hydrogel was 6.95.
The Mezoforte Duo EP device (Serial Number Mez 
120905-D), produced by Dr Derm Equipment Ltd. (Budapest, 
Hungary), was provided by the Derm Clinic of Anti-Aging 
Dermatology, Aesthetic Laser and Plastic Surgery (Budapest, 
Hungary). The device operates on the basis of a pulsed elec-
tromagnetic field. The polypropylene-covered treating head-
piece contains a plate electrode 25 mm in diameter indirectly 
contacting with the treated surface. Modulation was achieved 
with 1,800 Vpp (peak-to-peak voltage) pulses with a dura-
tion of 5 milliseconds, followed by a 20 milliseconds break. 
This pulse treatment was utilized on the abdominal surface 
for 2 minutes (2,200 periods/min), during which period the 
applied neostigmine-containing hydrogel was absorbed 
through the skin, with only a dry film layer remaining on 
the surface of the skin. A 10-minute waiting period ensued 
before the next EP-delivered neostigmine dose.
For iv administration, a neostigmine methylsulfate injec-
tion (Stigmosan™, Pharmamagist, Budapest, Hungary) was 
diluted in physiological saline solution. The cumulative 
neostigmine doses and recording protocol were the same 
as in the EP protocol. The period for iv administration was 
~20–30 seconds, and the recording of contractions was started 
2 minutes after the start of the neostigmine administration.
hPlc analysis
chemicals and reagents for hPlc
Analytical grade sodium dihydrogenphosphate and disodium 
hydrogenphosphate dodecahydrate were obtained from 
Sigma-Aldrich (Budapest, Hungary). High-performance liquid 
chromatography (HPLC) grade glacial acetic acid, acetonitrile, 
and methanol were purchased from Merck (Darmstadt, Ger-
many). Benzyltri-n-propylammonium chloride (internal stan-
dard) and neostigmine methylsulfate were from Sigma-Aldrich. 
The water used was purified and deionized with the Milli-Q 
system (Millipore, Milford, MA, USA).
hPlc system and conditions
The HPLC apparatus consisted of a Shimadzu system 
(Shimadzu Corporation, Kyoto, Japan) equipped with a 
solvent delivery system (LC-20AD), a DGU-20A
3
 on-line 
degasser, a SIL 20A HT autoinjector, a CTO-20A column 
oven, an SPD-M20A photodiode-array detector, and a CBM-
20A system controller. The chromatographic system was 
equipped with a Rheodyne Model 7125 injector (Rheodyne 
Corp., Cotati, CA, USA) with a 20 μL loop. The system 
control and data acquisition were performed with Shimadzu 
LC solution software (Shimadzu Corporation).
The chromatographic separations were performed on a 
PhenoSphere SCX (5 μm, 150×4.6 mm) analytical column 
(Phenomenex Inc., Budapest, Hungary), protected by a 5 μm 
guard column. The column temperature was maintained 
constant at 35°C. Separations were performed in isocratic 
mode. The mobile phase used for the separation consisted of 
0.5 M NaH
2
PO
4
 buffer (pH =3.5):acetonitrile =45:55 (v/v) 
pumped at a flow rate of 1 mL/min. The mobile phase was 
filtered by a Millipore vacuum filtration system equipped with 
a 0.45 μm pore size filter and degassed by ultrasonication. 
The detection wavelength was 200 nm.
Preparation of standard solutions and calibration 
samples
A stock solution of neostigmine methylsulfate (1 mg/mL) was 
prepared in the HPLC mobile phase and diluted with mobile 
phase to obtain a series of working standard solutions with con-
centrations ranging from 3 to 50 μg/mL. The internal standard 
stock solution (1 mg/mL in methanol) was further diluted to 
50 μg/mL with water. Stock solutions were stored at −20°C, 
and working solutions were kept refrigerated at 2°C–6°C. 
The working solutions were used to prepare seven calibration 
samples in blank plasma (0.3, 1, 3, 5, 10, 30, and 50 μg/mL).
sample extraction procedure
The blood samples were collected via the previously inserted 
polyethylene cannula 2 minutes after each EP or iv neostig-
mine treatment. The samples were centrifuged at 5,000× g 
for 10 minutes to obtain serum. Serum samples were stored 
at −70°C until HPLC analysis.
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An aliquot of plasma (200 μL) was combined with 
20 μL of internal standard working solution. The mixture 
was loaded into a Strata-X-CW 33u solid-phase extraction 
tube (Phenomenex Inc.) previously conditioned with 0.5 mL 
5% glacial acetic acid in methanol, 0.5 mL methanol, and 
0.5 mL 0.2 M Na
2
HPO
4
 (pH =9). The cartridge was washed 
with 1 mL of a 0.2 M Na
2
HPO
4
 (pH =9):methanol =90:10 
mixture (v/v). The neostigmine methylsulfate retained in 
the cartridge was eluted with 1 mL 5% glacial acetic acid 
in methanol into a glass tube. The eluate was evaporated to 
dryness under a stream of nitrogen at 40°C and reconstituted 
with 100 μL mobile phase, and 20 μL was then injected into 
the HPLC system.
calibration curve
The seven-point calibration curves, prepared in triplicate, 
exhibited good linearity (R2=0.9984) in the concentration 
range 0.3–50 μg/mL for neostigmine methylsulfate. The 
recovery of neostigmine methylsulfate from the plasma 
samples was 79.84%±3.52%. The limits of quantification 
and detection were 0.05 and 0.1 μg/mL, respectively.
Results
Neostigmine increased the cecal contractions after both iv 
and transdermal EP administration (Figure 2A). The calcu-
lated ED
50
 value for neostigmine was approximately twice 
as high after iv administration as compared with the EP 
route. However, this difference is statistically not significant. 
The calculated maximum increase in contractions was only 
20% lower after EP administration than that after iv treat-
ment (Table 1). The cecal contractile responses to iv- or 
EP-administered neostigmine did not differ significantly in 
the investigated dose interval (0.2–66.7 μg/kg). The cecal 
smooth muscle did not show any response to EP stimulation 
without neostigmine (Figure 2B).
A representative chromatogram for neostigmine plasma 
determination is presented in Figure 3. The chromatogram 
of blank rat plasma spiked with 10 μg/mL neostigmine 
gave a clear neostigmine peak with a retention time of 
7.73±0.31 minutes (Figure 3A). In neostigmine-treated rats, 
a smaller but identifiable peak was found at the same reten-
tion time as that of the neostigmine-spiked blank rat plasma 
(Figure 3B). The magnitudes of the peak of the internal 
standard were the same in both cases, indicating the reli-
ability of the method. The HPLC analysis of the neostigmine 
plasma levels revealed that the two routes of administration 
resulted in very similar drug concentrations. The neostigmine 
plasma concentrations were the same after both iv and EP 
administrations; statistically there was no difference between 
the two plasma curves (Figure 4).
When the cecal contractions were represented as a 
function of the plasma concentration of neostigmine, the 
concentration–response curves were similar to the dose–
response curves (Figure 5).
Discussion
There is an increasing need for new and noninvasive routes 
of drug administration in clinical practice. Moreover, there 
is a demand for fast and safe drug administration for acute 
care and even chronic treatment. The increasing numbers 
of peptide drugs have also given rise to a requirement for 
noninvasive therapy.16 Novel biological therapies involve 
peptide compounds, mainly monoclonal antibodies, and the 
antidiabetic or ovulation induction therapies also apply pep-
tide hormones. These peptide drugs are not applicable via oral 
administration because of their sensitivity to peptidases in the 
gastrointestinal tract. The most frequent route of administra-
tion of such compounds is subcutaneous administration, but 
many patients fear the needles, especially in self-treatment.
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Figure 2 The dose–response curves of neostigmine on cecal contractions after eP and iv administration in anesthetized rat.
Notes: (A) The cecal contractions were detected with strain gauge sensors. (B) cecal response to eP without neostigmine.
Abbreviations: eP, electroporation; iv, intravenous.
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EP is a method of noninvasive drug administration 
which is widely used for cosmetic interventions,17,18 delivery 
of genes into cells19 and experimental animals,20,21 or the 
delivery of anticancer agents into tumor cells.22 Attempts 
have been made to apply EP for transdermal drug delivery in 
systemic therapies.9 A number of papers have described the 
local action of EP-delivered drugs,23 but only a few reports 
can be found concerning the systemic applicability of this 
method for drug delivery.9,10,12
The electrodes and the electric pulse parameters are the 
key information in EP applications. Another way to apply 
electric pulses for drug delivery is iontophoresis. Iontophore-
sis applies a low intensity (,0.5 mA/cm2) electric field for a 
period of minutes or hours with low voltage (5–10 V or less). 
Direct current is usually used, but pulsed direct current can 
enhance the efficacy of iontophoresis if the pulse frequency 
is not too high.24 EP makes use of short (,1 second) and 
high-voltage pulses (.50 V), creating an aqueous pathway 
for transport through lipid bilayers of the skin.25 In our EP 
method, an amplitude-modulated sine wave radiofrequency 
current was utilized as the source of pulses for EP. The high 
voltage (1,800 Vpp) and the high pulse frequency (2,200/min) 
applied exclude the possibility of neostigmine being deliv-
ered by iontophoretic processes in our system.
We detected the systemic action of EP-delivered neo-
stigmine methylsulfate with plasma drug level control. In 
anesthetized rats, no adverse effects were experienced by EP. 
Neostigmine methylsulfate is a highly water-soluble com-
pound that is unable to penetrate through the barriers of the 
dermal lipid layers. Since neostigmine exerts a well expressed 
contracting effect on the gastrointestinal smooth muscle, we 
selected a part of the large intestine (the cecum) as the target 
organ of our measurements, and the contraction-increasing 
effects and plasma levels of EP-delivered neostigmine were 
compared with its effects after iv administration. For the 
detection of plasma levels of neostigmine, an HPLC setup 
was employed. Although the plasma concentration of neo-
stigmine was relatively low, the sensitivity of the method 
was sufficient for qualitative determination.
Somewhat surprisingly, no difference in cecal-contracting 
effect or plasma level of neostigmine was observed after 
2 minutes of EP and iv administration. EP may therefore be 
considered to be equivalent to iv administration for systemic 
drug delivery. Moreover, the action of neostigmine could 
be adjusted through the use of relatively small doses, which 
suggests that distinguished dosages can be applied via EP.
We also proved that the plasma concentrations of neo-
stigmine correlate with the increases in cecal contractions 
after both iv and EP administrations. This correlation is 
further evidence that EP-administered neostigmine reaches 
the circulation and is solely responsible for the measured 
physiological response.
EP can induce muscle contractions as an adverse effect. 
However, in our system, the EP did not have any direct 
contracting effect on the smooth muscle, and thus all the 
Table 1 The doses for the eD50 and emax effects of neostigmine 
on cecal contractions after eP and iv administration in rat
Values Neostigmine 
EP
Neostigmine 
iv
Significance
eD50 (μg/kg ± seM) 6.0±2.2 14.1±3.0 ns
emax (% ± seM) 82.8±12.7 104.6±30.4 ns
Note: Data expressed as mean ± seM (repeated iv treatment n=10, repeated 
transdermal eP treatment n=8).
Abbreviations: eD50, dose of neostigmine that provokes a response half way 
between the basal and the maximal response; emax, the maximal response obtained 
by neostigmine; EP, electroporation; iv, intravenous; NS, not significant; SEM, 
standard error of mean.
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Figure 3 representative chromatograms of rat plasma.
Notes: representative chromatograms of blank rat plasma spiked with 10 μg/ml neostigmine methylsulfate (A) and a rat plasma sample after electroporation-delivered 
neostigmine (20 μg/kg) (B).
Abbreviations: is, internal standard; maU, milliabsorption unit.
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registered changes in the cecal contractions were conse-
quences of the drug action.
There are some limitations of our study. The period for 
iv administration was ~20–30 seconds, and the recording of 
contractions was therefore started 2 minutes after the start of 
the injection in order to make the time frame similar to that 
of EP. The plasma concentration of an iv-administered drug is 
highest immediately after the injection, but the blood sample 
was collected after 2 minutes of iv delivery. This means that 
we missed the highest plasma peaks after iv administration, 
which may explain why the plasma curves are similar after 
iv and EP drug delivery. For the contractions, the neostig-
mine should be distributed in the large intestine tissue; this 
is not an immediate action, and we therefore suppose that 
any difference between the maximum effects of iv and EP 
drug delivery is not significant, or the distribution process 
equilibrates the difference. Another limitation is that the 
impulse of the applied EP parameters was constant; we 
did not test the effects of different voltages or pulse dura-
tions on the bowel action and plasma level of neostigmine. 
Further studies are necessary to reveal the threshold volt-
age needed to induce the systemic absorption of the drugs. 
However, with regard to the earlier and present findings, 
we have a good reason to suspect that EP works on the 
principle of all or nothing, opening all the biological barriers 
in the tissues or cell membranes at once.26 Additionally, we 
do not know what size of plate electrode should be used in 
humans. A diameter proportional to that used in rats would 
certainly be too large. On the other hand, the drug concentra-
tion of the hydrogel and the area of the treated surface can be 
modified easily to find the optimal setup for human therapy. 
Drugs with different chemical properties should also be tested 
with this delivery system in order to assess the applicability 
of this method.
The potential clinical application of EP may involve the 
rapid therapy of a life-threatening condition to replace iv 
treatment (eg, epileptic seizure or a cardiac arrest) and may 
make protein drug delivery (eg, insulin or low molecular 
weight heparin) easy and painless during self-administration 
by the patients.
Conclusion
We conclude that transdermal EP-delivered neostigmine 
elicits action equivalent to that of intravenous administration 
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both in time and intensity. Through EP, even low doses of 
water-soluble compounds can be delivered through the skin, 
which is promising for clinical practice. Although our find-
ings are potentially promising for the clinical application of 
EP for drug delivery, a number of questions remain to be 
clarified before human therapy can be initiated.
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